Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

World News: . []

CALGARY, Alberta, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris, France, from August 31 to September 4, 2019, the world’s largest cardiovascular conference. As detailed below, the Company will be presenting two posters on its lead compound – : (1) BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial; (2) Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism.

In addition, through an unrestricted grant, the Company is supporting an educational symposium during ESC 2019 titled: where key opinion leaders will review, among other related topics, the role of epigenetics and BET-inhibition as a novel strategy to improve outcomes in cardiovascular disease (“CVD”) patients.

The symposium faculty will include Dr. Peter Libby, Mallinckrodt Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital. Dr. Libby’s leading contributions to the understanding of inflammation biology and cardiovascular medicine are well recognized around the globe. The details of the symposium are also available below.

Dr. Libby commented, “Inflammation drives many cardiovascular complications, and regulation of inflammatory gene expression through epigenetic control provides a novel approach to its mitigation that merits clinical evaluation.”

“We are extremely pleased that Professors Libby, Landmesser, Jukema and Ray have chosen to participate in this important educational session during ESC 2019,” said Donald McCaffrey, President and CEO of Resverlogix. “The caliber of this faculty lends new weight to the growing recognition of the promise held by epigenetic therapies in the treatment of cardiovascular disease."

August 31, 2019

This symposium is funded by an unrestricted educational grant provided by Resverlogix.

Video Presentations & Symposium Highlights can be accessed (approximately 2 months post live event) once available.

Sept. 2, 2019

Sept. 3, 2019

Posters will be posted to the Company website once available.

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

Investor Relations Email: Phone: 403-254-9252Or visit our website:

More news and information about Resverlogix Corp

Published By:

Globe Newswire: 13:30 GMT Wednesday 14th August 2019

Published: .

Search for other references to "resverlogix" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us